MIPI - Mantle Cell Lymphoma Prognosis

Estimate prognosis in mantle cell lymphoma.

The global unit selector only affects unanswered questions
1.Age?
2.LDH?
3.LDH Upper Limit of Normal Value for your Lab?
4.WBC?
5.ECOG Performance Status?
6.Ki67 Value Known?
7.Ki67 - Cell Proliferation Index (Enter 0 if unknown)
Created by

1. Age?

Years
Created by
0/7 completed

About this Calculator

The Mantle Cell Lymphoma International Prognostic Index (MIPI) was derived from a data set of 455 advanced stage MCL patients treated in series of clinical trials in Germany/Europe. Of the evaluable population, approximately 18% were treated with high-dose therapy and stem cell transplantation in first remission. The MIPI is able to classify patients into three risk groups: low risk (median survival not reached after median 32 mos follow-up and 5-year OS rate of 60%), intermediate risk (median survival 51 months) and high risk (median survival 29 months). In addition to the 4 independent prognostic factors included in the model, the cell proliferation index (Ki-67) was also shown to have additional prognostic relevance. When the Ki67 is available, a biologic MIPI (MIPIb) can be calculated.

References

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.